Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 8.4%. This drop is a stark contrast from the S&P 500’s 5.4% gain.
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match.
The flip side though is that these lofty expectations make them particularly susceptible to drawdowns when market sentiment shifts.
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations.
However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
Growth is oxygen.
But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top S&P500 gainers and losers in today's pre-market session.
INSULET CORP (NASDAQ:PODD) shows strong revenue growth, high profitability, and a bullish technical setup, making it a noteworthy candidate for growth investors.
Looking back on patient monitoring stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including DexCom (NASDAQ:DXCM) and its peers.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Insulin delivery company Insulet Corporation (NASDAQ:PODD) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 28.8% year on year to $569 million. On top of that, next quarter’s revenue guidance ($608.2 million at the midpoint) was surprisingly good and 5.5% above what analysts were expecting. Its non-GAAP profit of $1.02 per share was 29.7% above analysts’ consensus estimates.
While the broader market has struggled with the S&P 500 down 1.8% since December 2024, Insulet has surged ahead as its stock price has climbed by 18.9% to $318.02 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Insulet (NASDAQ:PODD) and its peers.
INSULET CORP (NASDAQ:PODD) shows strong growth fundamentals and a bullish technical pattern, making it a stock worth watching for investors seeking growth opportunities.
